• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血阶段裂殖子表面蛋白与纳米颗粒结合可诱导有效的寄生虫抑制抗体。

Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies.

机构信息

University of Hawaii, School of Medicine, Department of Tropical Medicine, 651 Ilalo Street, BSB320 Honolulu, HI 96813, USA.

出版信息

Vaccine. 2011 Nov 8;29(48):8898-908. doi: 10.1016/j.vaccine.2011.09.070. Epub 2011 Sep 28.

DOI:10.1016/j.vaccine.2011.09.070
PMID:21963870
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3202662/
Abstract

In this proof-of-concept study we report the use of <15 nm, water soluble, inorganic nanoparticles as a vaccine delivery system for a blood stage malaria vaccine. The recombinant malarial antigen, Merozoite Surface Protein 1 (rMSP1) of Plasmodium falciparum served as the model vaccine. The rMSP1 was covalently conjugated to polymer-coated quantum dot CdSe/ZnS nanoparticles (QDs) via surface carboxyl groups, forming rMSP1-QDs. Anti-MSP1 antibody responses induced by rMSP1-QDs were found to have 2-3 log higher titers than those obtained with rMSP1 administered with the conventional adjuvants, Montanide ISA51 and CFA. Moreover, the immune responsiveness and the induction of parasite inhibitory antibodies were significantly superior in mice injected with rMSP1-QDs. The rMSP1-QDs delivered via intra-peritoneal (i.p.), intra-muscular (i.m.), and subcutaneous (s.c.) routes were equally efficacious. The high level of immunogenicity exhibited by the rMSP1-QDs was achieved without further addition of other adjuvant components. Bone marrow derived dendritic cells were shown to efficiently take up the nanoparticles leading to their activation and the expression/secretion of key cytokines, suggesting that this may be a mode of action for the enhanced immunogenicity. This study provides promising results for the use of water soluble, inorganic nanoparticles (<15 nm) as potent vehicles/platforms to enhance the immunogenicity of polypeptide antigens in adjuvant-free immunizations.

摘要

在这项概念验证研究中,我们报告了使用 <15nm、水溶性、无机纳米粒子作为一种疫苗传递系统,用于一种血阶段疟疾疫苗。重组疟原虫抗原,恶性疟原虫表面蛋白 1(rMSP1)作为模型疫苗。rMSP1 通过表面羧基与聚合物包覆的量子点 CdSe/ZnS 纳米粒子(QDs)共价偶联,形成 rMSP1-QDs。rMSP1-QDs 诱导的抗-MSP1 抗体反应的滴度比用常规佐剂 Montanide ISA51 和 CFA 给予的 rMSP1 获得的滴度高 2-3 个对数。此外,rMSP1-QDs 免疫的小鼠的免疫反应性和寄生虫抑制抗体的诱导明显优于 rMSP1 免疫的小鼠。通过腹膜内(i.p.)、肌肉内(i.m.)和皮下(s.c.)途径给予 rMSP1-QDs 同样有效。rMSP1-QDs 表现出的高免疫原性无需进一步添加其他佐剂成分。骨髓来源的树突状细胞被证明能够有效地摄取纳米粒子,导致其激活和关键细胞因子的表达/分泌,表明这可能是增强免疫原性的作用模式。这项研究为使用水溶性、无机纳米粒子(<15nm)作为增强无佐剂免疫中多肽抗原免疫原性的有效载体/平台提供了有前景的结果。

相似文献

1
Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies.血阶段裂殖子表面蛋白与纳米颗粒结合可诱导有效的寄生虫抑制抗体。
Vaccine. 2011 Nov 8;29(48):8898-908. doi: 10.1016/j.vaccine.2011.09.070. Epub 2011 Sep 28.
2
Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine.氧化铁纳米颗粒作为一种临床可接受的重组血期人类疟疾疫苗传递平台。
FASEB J. 2013 Mar;27(3):1153-66. doi: 10.1096/fj.12-218362. Epub 2012 Nov 29.
3
Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.聚肌苷酸-聚胞苷酸佐剂可显著增强 BALB/c 小鼠对恶性疟原虫裂殖子表面蛋白-1(42kDa 片段)的抑制抗体和 Th1 应答。
Med Microbiol Immunol. 2018 Apr;207(2):151-166. doi: 10.1007/s00430-018-0535-4. Epub 2018 Feb 3.
4
Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.一种嵌合恶性疟原虫裂殖子表面蛋白疫苗在夜猴中的免疫原性。
Malar J. 2016 Mar 15;15:159. doi: 10.1186/s12936-016-1226-5.
5
Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.定制亚单位疫苗免疫原性:通过使用腺病毒、痘病毒和蛋白佐剂疫苗组合针对恶性疟原虫 MSP1 来最大化抗体和 T 细胞应答。
Vaccine. 2010 Oct 18;28(44):7167-78. doi: 10.1016/j.vaccine.2010.08.068.
6
Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.含恶性疟原虫裂殖子表面蛋白-1 羧基端 19 kDa 片段和鼠伤寒沙门氏菌鞭毛蛋白 FliC 天然免疫激动剂的重组融合蛋白的免疫原性。
Vaccine. 2010 Apr 1;28(16):2818-26. doi: 10.1016/j.vaccine.2010.02.004. Epub 2010 Feb 17.
7
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.对重组恶性疟原虫裂殖子表面蛋白1(MSP1)的免疫:绢毛猴体内的保护作用与抗MSP1抗体滴度及体外寄生虫抑制活性密切相关。
Infect Immun. 2006 Aug;74(8):4573-80. doi: 10.1128/IAI.01679-05.
8
Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.来源于评估候选抗原恶性疟原虫 FVO 裂殖子表面蛋白-1(MSP1(42))经肌内注射与佐剂系统 AS01 联合使用的安全性、反应原性和免疫原性的两阶段 1 期研究结果。
Malar J. 2013 Jan 23;12:29. doi: 10.1186/1475-2875-12-29.
9
Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts.在不同免疫基因敲除小鼠中,佐剂辅助免疫诱导产生的抗裂殖子表面蛋白-1抗体的生物学活性。
Clin Vaccine Immunol. 2008 Aug;15(8):1145-50. doi: 10.1128/CVI.00058-08. Epub 2008 Jun 18.
10
Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.表达恶性疟原虫裂殖子表面蛋白-1(MSP-1(19))抗原的重组牛型结核分枝杆菌(rBCG)的免疫原性和体外保护效力。
Parasitol Res. 2011 Apr;108(4):887-97. doi: 10.1007/s00436-010-2130-5. Epub 2010 Nov 6.

引用本文的文献

1
Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.聚肌苷酸-聚胞苷酸佐剂可显著增强 BALB/c 小鼠对恶性疟原虫裂殖子表面蛋白-1(42kDa 片段)的抑制抗体和 Th1 应答。
Med Microbiol Immunol. 2018 Apr;207(2):151-166. doi: 10.1007/s00430-018-0535-4. Epub 2018 Feb 3.
2
The Use of Synthetic Carriers in Malaria Vaccine Design.合成载体在疟疾疫苗设计中的应用。
Vaccines (Basel). 2015 Oct 29;3(4):894-929. doi: 10.3390/vaccines3040894.
3
Recent advances in recombinant protein-based malaria vaccines.

本文引用的文献

1
Antigen-presenting dendritic cells rescue CD4-depleted CCR2-/- mice from lethal Histoplasma capsulatum infection.树突状细胞呈递抗原可使耗尽 CD4 的 CCR2-/- 小鼠免于致死性荚膜组织胞浆菌感染。
Infect Immun. 2010 May;78(5):2125-37. doi: 10.1128/IAI.00065-10. Epub 2010 Mar 1.
2
Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.疟疾初治成年人中含或不含 CPG 7909 的恶性疟原虫红内期疫苗 MSP1(42)-C1/Alhydrogel 的 1 期临床试验。
PLoS One. 2010 Jan 22;5(1):e8787. doi: 10.1371/journal.pone.0008787.
3
A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria.
基于重组蛋白的疟疾疫苗的最新进展。
Vaccine. 2015 Dec 22;33(52):7433-43. doi: 10.1016/j.vaccine.2015.09.093. Epub 2015 Oct 11.
4
Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.恶性疟原虫合成的层层膜微球疫苗可诱导保护性中和抗体和寄生虫特异性细胞免疫应答。
Vaccine. 2013 Apr 8;31(15):1898-904. doi: 10.1016/j.vaccine.2013.02.027. Epub 2013 Feb 26.
5
Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine.氧化铁纳米颗粒作为一种临床可接受的重组血期人类疟疾疫苗传递平台。
FASEB J. 2013 Mar;27(3):1153-66. doi: 10.1096/fj.12-218362. Epub 2012 Nov 29.
一种无佐剂的多肽纳米颗粒疫苗可对啮齿类疟疾提供持久保护。
J Immunol. 2009 Dec 1;183(11):7268-77. doi: 10.4049/jimmunol.0901957. Epub 2009 Nov 13.
4
ISCOMs and ISCOMATRIX.免疫刺激复合物及免疫刺激复合物基质
Vaccine. 2009 Jul 16;27(33):4388-401. doi: 10.1016/j.vaccine.2009.05.032. Epub 2009 May 28.
5
Current advances in research and clinical applications of PLGA-based nanotechnology.基于聚乳酸-羟基乙酸共聚物(PLGA)的纳米技术在研究和临床应用方面的当前进展。
Expert Rev Mol Diagn. 2009 May;9(4):325-41. doi: 10.1586/erm.09.15.
6
A vault nanoparticle vaccine induces protective mucosal immunity.一种穹顶纳米颗粒疫苗可诱导保护性黏膜免疫。
PLoS One. 2009;4(4):e5409. doi: 10.1371/journal.pone.0005409. Epub 2009 Apr 30.
7
Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery.壳聚糖微球和纳米球:药物与DNA递送的制备及应用
Mini Rev Med Chem. 2009 Apr;9(4):463-9. doi: 10.2174/138955709787847976.
8
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.在肯尼亚西部,能引发高抗原特异性抗体浓度的血液期疟疾疫苗对幼儿并无保护作用。
PLoS One. 2009;4(3):e4708. doi: 10.1371/journal.pone.0004708. Epub 2009 Mar 5.
9
Nanocarriers for systemic and mucosal vaccine delivery.用于全身和黏膜疫苗递送的纳米载体。
Recent Pat Drug Deliv Formul. 2007;1(1):1-9. doi: 10.2174/187221107779814140.
10
Nanocarriers as an emerging platform for cancer therapy.纳米载体作为一种新兴的癌症治疗平台。
Nat Nanotechnol. 2007 Dec;2(12):751-60. doi: 10.1038/nnano.2007.387.